PT3028718T - Tratamento da esclerose múltipla (em) com campath-1h - Google Patents

Tratamento da esclerose múltipla (em) com campath-1h

Info

Publication number
PT3028718T
PT3028718T PT151914918T PT15191491T PT3028718T PT 3028718 T PT3028718 T PT 3028718T PT 151914918 T PT151914918 T PT 151914918T PT 15191491 T PT15191491 T PT 15191491T PT 3028718 T PT3028718 T PT 3028718T
Authority
PT
Portugal
Prior art keywords
campath
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
PT151914918T
Other languages
English (en)
Original Assignee
Alcafleu Man Gmbh & Co Kg
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38734000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3028718(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcafleu Man Gmbh & Co Kg, Genzyme Corp filed Critical Alcafleu Man Gmbh & Co Kg
Publication of PT3028718T publication Critical patent/PT3028718T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PT151914918T 2006-09-13 2007-09-11 Tratamento da esclerose múltipla (em) com campath-1h PT3028718T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84425106P 2006-09-13 2006-09-13
EP06090169 2006-09-14

Publications (1)

Publication Number Publication Date
PT3028718T true PT3028718T (pt) 2022-06-09

Family

ID=38734000

Family Applications (2)

Application Number Title Priority Date Filing Date
PT151914918T PT3028718T (pt) 2006-09-13 2007-09-11 Tratamento da esclerose múltipla (em) com campath-1h
PT78023488T PT2066352E (pt) 2006-09-13 2007-09-11 Tratamento da esclerose múltipla (em) com campath-1h

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT78023488T PT2066352E (pt) 2006-09-13 2007-09-11 Tratamento da esclerose múltipla (em) com campath-1h

Country Status (21)

Country Link
EP (4) EP3028718B1 (pt)
JP (6) JP5872756B2 (pt)
KR (2) KR101583587B1 (pt)
CN (1) CN102652832A (pt)
AR (1) AR062779A1 (pt)
BR (1) BRPI0716929A8 (pt)
CA (1) CA2662531A1 (pt)
CY (1) CY2016019I2 (pt)
DK (1) DK2066352T3 (pt)
ES (2) ES2917882T3 (pt)
HR (1) HRP20160211T1 (pt)
HU (2) HUE026740T2 (pt)
IL (3) IL197236A (pt)
LT (1) LTC2066352I2 (pt)
LU (1) LU93092I2 (pt)
MX (2) MX354080B (pt)
PL (2) PL2066352T3 (pt)
PT (2) PT3028718T (pt)
RS (1) RS54658B1 (pt)
SI (1) SI2066352T1 (pt)
WO (1) WO2008031626A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2917882T3 (es) 2006-09-13 2022-07-12 Alcafleu Man Gmbh & Co Kg Tratamiento de esclerosis múltiple (MS) con Campath-1H
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN110546167A (zh) * 2017-04-21 2019-12-06 建新公司 以抗-cd52抗体治疗多发性硬化症
WO2020123789A1 (en) * 2018-12-12 2020-06-18 Pretzer Aboff Ingrid Vibrational device and methods for mitigating symptoms of freezing of gait

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
ES2917882T3 (es) 2006-09-13 2022-07-12 Alcafleu Man Gmbh & Co Kg Tratamiento de esclerosis múltiple (MS) con Campath-1H

Also Published As

Publication number Publication date
CY2016019I1 (el) 2016-10-05
PL2066352T3 (pl) 2016-05-31
PL3028718T3 (pl) 2022-11-21
KR101583587B1 (ko) 2016-01-08
IL197236A (en) 2015-08-31
JP2018024655A (ja) 2018-02-15
IL257341A (en) 2018-03-29
KR20090063215A (ko) 2009-06-17
DK2066352T3 (en) 2016-02-29
HRP20160211T1 (hr) 2016-03-25
EP2433649A3 (en) 2012-10-31
JP2019167385A (ja) 2019-10-03
AR062779A1 (es) 2008-12-03
CN102652832A (zh) 2012-09-05
MX2009002660A (es) 2009-06-11
JP6257287B2 (ja) 2018-01-10
EP2444104A3 (en) 2012-10-24
KR20150039879A (ko) 2015-04-13
BRPI0716929A8 (pt) 2019-02-05
AU2007296857A1 (en) 2008-03-20
LTC2066352I2 (lt) 2017-09-25
JP2010503631A (ja) 2010-02-04
IL240394A0 (en) 2015-09-24
JP5872756B2 (ja) 2016-03-01
CA2662531A1 (en) 2008-03-20
IL240394B (en) 2018-02-28
SI2066352T1 (sl) 2016-05-31
JP2014058555A (ja) 2014-04-03
ES2563068T3 (es) 2016-03-10
LU93092I2 (de) 2016-08-01
EP2444104A2 (en) 2012-04-25
IL197236A0 (en) 2011-08-01
HUS1600028I1 (hu) 2016-07-28
CY2016019I2 (el) 2016-10-05
EP3028718A1 (en) 2016-06-08
EP2433649A2 (en) 2012-03-28
RS54658B1 (sr) 2016-08-31
JP2016175929A (ja) 2016-10-06
HUE026740T2 (en) 2016-07-28
EP3028718B1 (en) 2022-03-23
EP2066352B1 (en) 2015-12-02
HK1136773A1 (en) 2010-07-09
MX354080B (es) 2018-02-12
RU2009113665A (ru) 2010-10-20
JP2021107423A (ja) 2021-07-29
ES2917882T3 (es) 2022-07-12
BRPI0716929A2 (pt) 2013-09-17
PT2066352E (pt) 2016-03-31
WO2008031626A1 (en) 2008-03-20
EP2066352A1 (en) 2009-06-10
LTPA2016019I1 (lt) 2016-06-27

Similar Documents

Publication Publication Date Title
IL197818A0 (en) Multiple sclerosis therapy
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
IL192555A0 (en) Method of treating multiple sclerosis
IL257341A (en) Treatment of multiple sclerosis with campath–1h
AU312971S (en) Patient interface
PL1983984T3 (pl) Leczenie stwardnienia guzowatego
IL193094A0 (en) Improved antitumoral treatments
GB0624874D0 (en) Treatment
GB0702931D0 (en) Skin application
GB0909297D0 (en) Composition for the treatment of skin conditions
ZA201000225B (en) Treatment of depression
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
GB0600692D0 (en) Well treatment
AU313136S (en) Patient interface
GB0608655D0 (en) Therapeutic Treatment
GB0610909D0 (en) Therapeutic treatment
GB0607952D0 (en) Novel treatment
GB0604460D0 (en) Treatment
GB0618403D0 (en) Treatment of amyotrophic lateral sclerosis
GB0609792D0 (en) The treatment of multiple sclerosis
GB0614058D0 (en) Treatment for multiple sclerosis
GB0602857D0 (en) The treatment of sialorrhoea
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0625602D0 (en) Treatment of sialorrhoea
GB0610376D0 (en) Therapeutic treatment